Autologous haematopoietic stem cell transplantation for paediatric solid tumours

Bailliere's Best Practice in Clinical Haematology

Volumn 12, Issue 1-2, 1999, Pages 247-259

  Michon, Jean ^a   Schleiermacher, Gudrun ^a  

^a INSTITUT CURIE   (France)

Author keywords

Alkylating agents; Autologous haematopoietic stem cell graft; High dose chemotherapy; Paediatric solid tumours; Purging; Total body irradiation

Indexed keywords

BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; TENIPOSIDE; THIOTEPA; VINCRISTINE;

ADOLESCENT; AUTOTRANSPLANTATION; BONE MARROW METASTASIS; CANCER RECURRENCE; CHEMOTHERAPY; CHILD; EWING SARCOMA; GASTROINTESTINAL SYMPTOM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MEDULLOBLASTOMA; NEPHROBLASTOMA; NEUROBLASTOMA; OSTEOSARCOMA; PRIORITY JOURNAL; RETINOBLASTOMA; REVIEW; RHABDOMYOSARCOMA; SOLID TUMOR; TREATMENT INDICATION;

EID: 0032713311     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.1999.0021     Document Type: Article

References (77)

1. Frei E & Canellos GP. Dose: a critical factor in cancer chemotherapy. American Journal of Medicine 1980; 69: 585-594.
2. Cheung NK, Heller G, Kushner BH et al. Stage IV neuroblastoma more than 1 year of age at diagnosis: major response to chemotherapy and survival durations correlated strongly with dose intensity. Progress in Clinical and Biological Research 1991; 366: 567-573.
3. Hartmann O, Vassal G, Valteau D et al. Autologous bone marrow transplantation in pediatric solid tumors: phase II studies. Bone Marrow Transplantation 1991; 7 (supplement 3): 106-108.
4. Antman K, Eder JP, Elias A et al. High-dose thiotepa alone and in combination regimens with bone marrow support. Seminars in Oncology 1990; 17: 33-38.
5. Kletzel M, Kearns GL, Wells TG & Thompson HC Jr. Pharmacokinetics of high dose thiotepa in children undergoing autologous bone marrow transplantation. Bone Marrow Transplantation 1992; 10: 171-175.
6. Saarinen UM, Hovi L, Makipernaa A & Riikonen P. High-dose thiotepa with autologous bone marrow rescue in pediatric solid tumors. Bone Marrow Transplantation 1991; 8: 369-376.
7. Lucidarme N, Valteau-Couanet D, Oberlin O et al. Phase II study of high-dose thiotepa with hematopoietic stem cell transplantation in children with solid tumors. Bone Marrow Transplantation 1998; 22: 535-540.
8. Deacon JM, Wilson PA & Peckham MJ. The radiobiology of human neuroblastoma. Radiotherapy and Oncology 1985; 3: 201-209.
9. Philip T, Zucker JM, Bernard JL et al. Improved survival at 2 and 5 years in the LMCEI unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: is cure possible in a small subgroup? Journal of Clinical Oncology 1991; 9: 1037-1044.
10. Pinkerton CR, Philip T, Biron P et al. High-dose melphalan, vincristine, and total-body irradiation with autologous bone marrow transplantation in children with relapsed neuroblastoma: a phase II study. Medical and Pediatric Oncology 1987; 15: 236-240.
11. Brauner R, Adan L, Souberbielle JC et al. Contribution of growth hormone deficiency to the growth failure that follows bone marrow transplantation. Journal of Pediatrics 1997; 130: 785-792.
12. Neve V, Foot ABM, Michon J et al. Longitudinal clinical and functional pulmonary follow-up after megatherapy, fractionated total body irradiation and autologous bone marrow transplantation for metastatic neuroblastoma. Medical and Pediatric Oncology 1999; 32: 170-176.
13. Hartmann O, Valteau-Couanet D, Benhamou E et al. Stage IV neuroblastoma in patients over 1 year of age at diagnosis: consolidation of poor responders with combined busulfan, cyclophosphamide and melphalan followed by in vitro mafosfamide-purged autologous bone marrow transplantation. European Journal of Cancer 1997, 33: 2126-2129.
14. Kletzel M, Abella EM, Sandler ES et al. Thiotepa and cyclophosphamide with stem cell rescue for consolidation therapy for children with high-risk neuroblastoma: a phase I/II study of the Pediatric Blood and Marrow. Journal of Pediatric Hematology/Oncology 1998; 20: 49-54.
15. Lasky LC, Fox SB, Smith J & Bostrom B. Collection and use of peripheral blood stem cells in very small children. Bone Marrow Transplantation 1991; 7: 281-284.
16. Takaue Y, Kawano Y, Abe T et al. Collection and transplantation of peripheral blood stem cells in very small children weighting 20 kg or less. Blood 1995; 86: 372-380.
17. + cell immunoselection from G-CSF-alone-primed peripheral blood in children with low body mass. British Journal of Haematology 1995; 91: 431-433.
18. Hartmann O, Le Corroller AG, Blaise D et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Annals of Internal Medicine 1997; 126: 600-607.
19. Kanold J, Berger M, Halle P et al. Kinetics of hematopoietic progenitor cell release induced by G-CSF-alone in children with solid tumors and leukemias. Bone Marrow Transplantation 1998; 21: 59-63.
20. Diaz MA, Villa M, Alegre A et al. Collection and transplantation of peripheral blood progenitor cells mobilized by G-CSF alone in children with malignancies. British Journal of Haematology 1996; 94: 148-154.
21. Klingebiel T, Handgretinger R, Herter M et al. Autologous transplantation with peripheral blood stem cells in children and young adults after myeloablative treatment: nonrandomized comparison between GM-CSF and G-CSF for mobilization. Journal of Hematotherapy 1995; 4: 307-314.
22. Pinkerton CR. ENSG 1-randomised study of high-dose melphalan in neuroblastoma. Bone Marrow Transplantation 1991; 7: 112-113.
23. Ladenstein R, Philip T & Gardner H. Autologous stem cell transplantation for solid tumors in children. Current Opinion in Pediatrics 1997; 9: 55-69.
24. Hartmann O, Valteau-Couanet D, Lapierre V et al. Stage IV neorublastoma over 1 year of age autografted: the combination used in the conditioning regimen is the major prognostic factor. Medical and Pediatric Oncology 1997; 29: 320 (abstract 0-19).
25. Ladenstein R, Philip T, Lasset C et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. Journal of Clinical Oncology 1998; 16: 953-965.
26. Kushner BH, La Quaglia MP, Bonilla MA et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. Journal of Clinical Oncology 1994; 12: 2607-2613.
27. Matthay KK, Harris R, Reynolds CP et al. Improved event-free survival for autologous bone marrow transplantation vs chemotherapy in neuroblastoma: a phase III randomized children's cancer group study. Journal of Clinical Oncology 1998; 17: 525a (abstract 2018).
28. Treleaven JG, Gibson FM, Ugelstad J et al. Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microspheres. Lancet 1984; i: 70-73.
29. Matthay KK, Seeger RC, Reynolds CP et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Children's Cancer Group. Journal of Clinical Oncology 1994; 12: 2382-2389.
30. Matthay KK, Atkinson JB, Stram DO et al. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Children's Cancer Group pilot study. Journal of Clinical Oncology 1993; 11: 2226-2233.
31. Sibley GS, Mundt AJ, Goldman S et al. Patterns of failure following total body irradiation and bone marrow transplantation with or without a radiotherapy boost for advanced neuroblastoma. International Journal of Radiation Oncology, Biology, Physics 1995; 32: 1127-1135.
32. Rill DR, Santana VM, Roberts WM et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994, 84: 380-383.
33. + progenitor cells highly purified by magnetic-activated cell sorting. Bone Marrow Transplantation 1998; 21: 987-993.
34. Reynolds CP, Villablanca JG, Stram DO et al. 13-cis-retinoic acid after intensive consolidation therapy for neuroblastoma improves event-free survival: a randomized children's cancer group study. Journal of Clinical Oncology 1998; 17: 2a (abstract 5).
35. Cheung N-KV, Kushner BH, Cheung IY et al. Anti-GD2 antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more that 1 year of age. Journal of Clinical Oncology 1998; 16: 3053-3060.
36. Michon J, Negrier S, Coze C et al. Administration of high-dose recombinant interleukin 2 after autologous bone marrow transplantation in patients with neuroblastoma: toxicity, efficacy and survival. A Lyon-Marseille-Curie-east of France Group Study. Progress in Clinical and Biological Research 1994; 385: 293-300.
37. Bowman L, Grossmann M, Rill D et al. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood 1998; 6: 1941-1949.
38. Delattre O, Zucman J, Melot T et al. The Ewing family of tumors - a subgroup of small-round-cell tumors defined by specific chimeric transcripts. New England Journal of Medicine 1994; 331: 294-299.
39. Fagnou C, Michon J, Peter M et al. Presence of tumor cells in bone marrow but not in blood is associated with adverse prognosis in patients with Ewing's tumor. Societe Francaise d'Oncologie Pediatrique. Journal of Clinical Oncology 1998; 16: 1707-1711.
40. Jaffe N, Paed D, Traggis D et al. Improved outlook for Ewing's sarcoma with combination chemotherapy (vincristine, actinomycin D and cyclophosphamide) and radiation therapy. Cancer 1976; 38: 1925-1930.
41. Burgert EO Jr, Nesbit ME, Garnsey LA et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. Journal of Clinical Oncology 1990; 8: 1514-1524.
42. Gasparini M, Lombardi F, Ballerini E et al. Long-term outcome of patients with monostotic Ewing's sarcoma treated with combined modality. Medical and Pediatric Oncology 1994; 23: 406-412.
43. Craft A, Cotterill S, Malcolm A et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: the second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's tumor study. Journal of Clinical Oncology 1998; 16: 3628-3633.
44. Kushner BH, Meyers PA, Gerald WL et al. Very high-dose short-term chemotherapy for poor risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. Journal of Clinical Oncology 1995; 13: 2796-2804.
45. Paulussen M, Ahrens S, Craft AW et al. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. Journal of Clinical Oncology 1998; 16: 3044-3052.
46. Cangir A, Vietti TJ, Gehan EA et al. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. Cancer 1990; 66: 887-893.
47. Paulussen M, Ahrens S, Burdach S et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma. Annals of Oncology 1998; 9: 275-281.
48. Oberlin O, Patte C, Demeocq F et al. The response to initial chemotherapy as a prognostic factor in localized Ewing's sarcoma. European Journal of Cancer and Clinical Oncology 1985; 21: 463-467.
49. Valteau-Couanet D, Michon J, Plouvier E et al. Treatment of metastatic Ewing's sarcoma with busulfan and melphalan consolidation high dose chemotherapy. A study of the French Society of Pediatric Oncology (abstract 0-109). Medical and Pediatric Oncology 1996; 27: 238.
50. Atra A, Whelan JS, Calvagna V et al. High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma. Bone Marrow Transplantation 1997; 20: 843-846.
51. Horowitz ME, Kinsella TJ, Wexler LH et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. Journal of Clinical Oncology 1993; 11: 1911-1918.
52. Stewart DA, Gyonyor E, Paterson AH et al. High-dose melphalan +/- total body irradiation and autologous hematopoietic stem cell rescue for adult patients with Ewing's sarcoma or peripheral neuroectodermal tumor. Bone Marrow Transplantation 1996; 18: 315-318.
53. Burdach S, Jurgens H, Peters C et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. Journal of Clinical Oncology 1993; 11: 1482-1488.
54. Ladenstein R, Hartmann O, Pinkerton R et al. A multivariate and matched pair analysis on high-risk Ewing tumors patients undergoing MGT/SCR in Europe. Bone Marrow Transplantation 1998; 21: S227 (abstract).
55. Burdach S, Nurnberger W, Laws HJ et al. Myeloablative therapy, stem cell rescue and gene transfer in advanced Ewing tumors. Bone Marrow Transplantation 1996; 18: S67-S68.
56. Crist W, Gehan EA, Ragab AH et al. The Third Intergroup Rhabdomyosarcoma Study. Journal of Clinical Oncology 1995; 13: 610-630.
57. Horowitz ME, Etcubanas E, Christensen ML et al. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. Journal of Clinical Oncology 1988; 6: 308-314.
58. Bagnulo S, Perez DJ, Barett A et al. High dose melphalan and autologous bone marrow transplantation for solid tumours of childhood. European Peadiatric Haematology and Oncology 1985; 2: 123-133.
59. Belasco JB, Mitchell CD, Rohrbaugh T & Rosenstock J. IV melphalan in children. Cancer Treatment Reports 1987; 71: 1277-1278.
60. Pinkerton CR, Groot-Loonen J, Barrett A et al. Rapid VAC high dose melphalan regimen, a novel chemotherapy approach in childhood soft tissue sarcomas. British Journal of Cancer 1991; 64: 381-385.
61. Koscielniak E, Rodary C, Flamant F et al. Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: a retrospective European multi-center analysis. Medical and Pediatric Oncology 1992; 20: 209-214.
62. Raney RB Jr, Tefft M, Maurer HM et al. Disease patterns and survival rate in children with metastatic soft-tissue sarcoma. A report from the Intergroup Rhabdomyosarcoma Study (IRS)-I. Cancer 1988; 62: 1257-1266.
63. Koscielniak E, Klingebiel TH, Peters C et al. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplantation 1997; 19: 227-231.
64. Pein F, Michon J, Valteau-Couanet D et al. High-dose melphalan, etoposide and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study. Journal of Clinical Oncology 1998; 16: 3295-3301.
65. Pein F, Tournade MF, Zucker JM et al. Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms' tumor - a phase II study by the French Society of Pediatric Oncology. Journal of Clinical Oncology 1994; 12: 931-936.
66. Garaventa A, Hartmann O, Bernard JL et al. Autologous bone marrow transplantation for pediatric Wilms' tumor: the experience of the European Bone Marrow Transplantation Solid Tumor Registry. Medical and Pediatric Oncology 1994; 22: 11-14.
67. Duffner PK, Horowitz ME, Krischer JP et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. New England Journal of Medicine 1993; 328: 1725-1731.
68. Wolff NS. High dose therapy in brain tumors: rationale, results and future prospects. In Armiateg JO, Antmann KH (eds). High-dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells, 2nd edn, pp 879-888. Baltimore: Williams & Wilkins, 1995.
69. Dupuis-Girod S, Hartmann O, Benhamou E et al. Will high dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma? Journal of Neuro-Oncology 1996; 27: 87-98.
70. Finlay JL, Goldman S, Wong MC et al. Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group. Journal of Clinical Oncology 1996; 14: 2495-2503.
71. Grill J, Kalifa C, Doz F et al. A high-dose busulfan-thiotepa combination followed by autologous bone marrow transplantation in childhood recurrent ependymoma. A phase-II study. Pediatric Neurosurgery 1996; 25: 7-12.
72. Mason WP, Grovas A, Halpern S et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. Journal of Clinical Oncology 1998; 16: 210-221.
73. Dunkel IJ, Boyett JM, Yates A et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group. Journal of Clinical Oncology 1998; 16: 222-228.
74. Doz F, Neuenschwander S, Plantaz D et al. Etoposide and carboplatin in extraocular retinoblastoma: a study by the Societe Francaise d'Oncologie Pediatrique. Journal of Clinical Oncology 1995; 13: 902-909.
75. Namouni F, Doz F, Tanguy ML et al. High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: a SFOP and SFGM study. European Journal of Cancer 1997; 33: 2368-2375.
76. Schvartzman E, Chantada G, Fandino A et al. Results of a stage-based protocol for the treatment of retinoblastoma. Journal of Clinical Oncology 1996; 14: 1532-1536.
77. Tabone MD, Kalifa C, Rodary C et al. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. Journal of Clinical Oncology 1994; 12: 2614-2620.